<DOC>
	<DOC>NCT00373490</DOC>
	<brief_summary>This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.</brief_summary>
	<brief_title>A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)</brief_title>
	<detailed_description />
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients with histologically or cytologically diagnosed solid tumor in whom no standard therapy is available or the malignancy is refractory to standard therapy Patients with history of immunotherapy, radiotherapy, surgery, or chemotherapy during the previous 4 weeks Any uncontrolled concomitant illness Pregnant or breastfeeding Serious drug or food allergy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>